|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
EP4218801A3
(en)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
MY159787A
(en)
|
2006-06-02 |
2017-01-31 |
Regeneron Pharma |
High affinity antibodies to human il-6 receptor
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
EP2139924B1
(en)
|
2007-03-29 |
2016-07-06 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
AU2008255350B2
(en)
|
2007-05-31 |
2014-07-10 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
|
WO2009041613A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗体定常領域改変体
|
|
PL2202245T3
(pl)
|
2007-09-26 |
2017-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
|
|
WO2009103791A1
(en)
*
|
2008-02-22 |
2009-08-27 |
Genmab A/S |
Methods for assissing the risk of adverse events upon treatment with igg4 antibodies
|
|
EP3153524B1
(en)
|
2008-12-03 |
2025-04-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
JP2012515556A
(ja)
*
|
2009-01-23 |
2012-07-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
|
|
NZ596839A
(en)
|
2009-05-04 |
2014-01-31 |
Abbott Res Bv |
Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
JP2013519682A
(ja)
*
|
2010-02-11 |
2013-05-30 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃｄ２００抗体を使用する治療方法
|
|
ES2602971T3
(es)
|
2010-03-02 |
2017-02-23 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo modificado
|
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
|
JP6055312B2
(ja)
|
2010-03-10 |
2017-01-11 |
ゲンマブ エー／エス |
Ｃ−ｍｅｔに対するモノクローナル抗体
|
|
PH12012501761A1
(en)
|
2010-03-17 |
2012-11-12 |
Abbott Res Bv |
Anti-nerve growth factor (ngf) antibody compositions
|
|
CA2796181C
(en)
*
|
2010-04-20 |
2023-01-03 |
Genmab A/S |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
US9717777B2
(en)
|
2010-05-05 |
2017-08-01 |
Rappaport Family Institute For Research In The Medical Sciences |
Use of CCL1 in therapy
|
|
US9352000B2
(en)
|
2010-05-05 |
2016-05-31 |
Rappaport Family Institute For Research In The Medical Sciences |
Use of CCL1 in therapy
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
CN107253992B
(zh)
|
2010-05-27 |
2022-03-11 |
根马布股份公司 |
针对her2的单克隆抗体
|
|
SMT201700547T1
(it)
|
2010-06-15 |
2018-01-11 |
Genmab As |
Coniugati di farmaco anticorpo umano contro il fattore tissutale
|
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
GB201014033D0
(en)
*
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
CN103298937B
(zh)
|
2010-11-17 |
2016-05-25 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
|
NZ611076A
(en)
|
2010-12-01 |
2015-09-25 |
Alderbio Holdings Llc |
Anti-ngf compositions and use thereof
|
|
CA2830254C
(en)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Fc variants
|
|
EP4520771A3
(en)
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
CN103796677B
(zh)
|
2011-04-20 |
2019-08-16 |
健玛保 |
针对her2和cd3的双特异性抗体
|
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
JP6180408B2
(ja)
|
2011-06-13 |
2017-08-16 |
アブゲノミクス コーペラティフ ユー．エー． |
抗ｐｓｇｌ−１抗体およびその使用
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
PL2766397T3
(pl)
|
2011-10-11 |
2018-10-31 |
F.Hoffmann-La Roche Ag |
Ulepszone składanie przeciwciał bispecyficznych
|
|
WO2013060867A2
(en)
|
2011-10-27 |
2013-05-02 |
Genmab A/S |
Production of heterodimeric proteins
|
|
CN109111524B
(zh)
|
2011-10-31 |
2022-10-28 |
中外制药株式会社 |
控制了重链与轻链的缔合的抗原结合分子
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
BR112015018438A2
(pt)
*
|
2013-01-31 |
2017-07-18 |
Seoul Nat Univ R&Db Foundation |
anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CN103193882B
(zh)
*
|
2013-03-29 |
2014-11-05 |
浙江大学 |
胚胎干细胞特异性标志物GM-CSFRα及其应用
|
|
US10935554B2
(en)
|
2013-08-23 |
2021-03-02 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
CN105764922B
(zh)
|
2013-09-27 |
2020-07-17 |
中外制药株式会社 |
多肽异源多聚体的制备方法
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
AU2015222757B2
(en)
|
2014-02-28 |
2020-10-08 |
Allakos Inc. |
Methods and compositions for treating Siglec-8 associated diseases
|
|
KR102248804B1
(ko)
*
|
2014-03-12 |
2021-05-11 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
SG11201607983YA
(en)
|
2014-03-28 |
2016-10-28 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
|
RU2718692C2
(ru)
|
2014-05-29 |
2020-04-13 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
|
|
CN106456734A
(zh)
*
|
2014-05-29 |
2017-02-22 |
免疫医疗有限责任公司 |
Ox40l融合蛋白及其用途
|
|
RU2714153C2
(ru)
*
|
2014-06-12 |
2020-02-12 |
Ф. Хоффманн-Ля Рош Аг |
СПОСОБ ОТБОРА АНТИТЕЛ С МОДИФИЦИРОВАННЫМ ВЗАИМОДЕЙСТВИЕМ С FcRn
|
|
KR102130600B1
(ko)
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
BR122020025583B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
US10435470B2
(en)
|
2014-08-05 |
2019-10-08 |
Cb Therapeutics, Inc. |
Anti-PD-L1 antibodies
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
TWI576112B
(zh)
*
|
2014-10-24 |
2017-04-01 |
國立陽明大學 |
巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用以保護胰臟及防止血糖升高的用途
|
|
LT3699198T
(lt)
|
2014-11-17 |
2025-05-12 |
Regeneron Pharmaceuticals, Inc. |
Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
RS62332B1
(sr)
|
2014-11-26 |
2021-10-29 |
Xencor Inc |
Heterodimerna antitela koja vezuju cd3 i cd20
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ａｘｌに対するヒトモノクローナル抗体
|
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
SG11201706024YA
(en)
|
2015-01-26 |
2017-08-30 |
Macrogenics Inc |
Multivalent molecules comprising dr5-binding domains
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3277725B1
(en)
|
2015-03-30 |
2020-11-25 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
WO2016193380A1
(en)
|
2015-06-02 |
2016-12-08 |
Novo Nordisk A/S |
Insulins with polar recombinant extensions
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
CA2987797A1
(en)
*
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
|
ES2898958T3
(es)
|
2015-07-30 |
2022-03-09 |
Macrogenics Inc |
Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
|
|
CN108289953B
(zh)
|
2015-09-29 |
2022-03-11 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
MA43348A
(fr)
|
2015-10-01 |
2018-08-08 |
Novo Nordisk As |
Conjugués de protéines
|
|
EP3359192A4
(en)
|
2015-10-08 |
2019-05-01 |
MacroGenics, Inc. |
COMBINATION THERAPY FOR CANCER TREATMENT
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
MA44082A
(fr)
|
2015-12-14 |
2018-10-24 |
Macrogenics Inc |
Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
|
|
US11649262B2
(en)
|
2015-12-28 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
|
CA3013333A1
(en)
|
2016-02-26 |
2017-08-31 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
|
MX2018010988A
(es)
|
2016-03-14 |
2019-01-21 |
Chugai Pharmaceutical Co Ltd |
Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
|
|
KR102640157B1
(ko)
|
2016-03-22 |
2024-02-27 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
인간화 항-클라우딘-1 항체 및 이의 용도
|
|
WO2017176525A1
(en)
*
|
2016-04-04 |
2017-10-12 |
Promab Biotechnologies, Inc. |
Car having replicated binding motifs in a co-stimulatory domain
|
|
MX2018012648A
(es)
|
2016-04-28 |
2019-01-30 |
Chugai Pharmaceutical Co Ltd |
Preparaciones que contienen anticuerpos.
|
|
ES2912453T3
(es)
|
2016-05-06 |
2022-05-26 |
Inst Nat Sante Rech Med |
Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
|
|
CN109475627B
(zh)
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
AU2017293423B2
(en)
|
2016-07-05 |
2023-05-25 |
Beone Medicines I Gmbh |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
AU2017313085B2
(en)
|
2016-08-19 |
2024-06-20 |
Beone Medicines I Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
|
MA46534A
(fr)
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
WO2018118713A1
(en)
|
2016-12-22 |
2018-06-28 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
TWI856437B
(zh)
|
2017-01-20 |
2024-09-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
TW202421659A
(zh)
|
2017-01-20 |
2024-06-01 |
美商健臻公司 |
骨靶向抗體
|
|
GB201701194D0
(en)
|
2017-01-24 |
2017-03-08 |
Capella Bioscience Ltd |
Antigen binding molecules that bind light
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
WO2018166461A1
(en)
*
|
2017-03-14 |
2018-09-20 |
Sunshine Lake Pharma Co., Ltd. |
Dual-target fusion proteins comprising the fc portion of an immunoglobulin
|
|
WO2018185131A2
(en)
|
2017-04-05 |
2018-10-11 |
Novo Nordisk A/S |
Oligomer extended insulin-fc conjugates
|
|
EP3606952A1
(en)
|
2017-04-07 |
2020-02-12 |
Miltenyi Biotec GmbH |
POLYPEPTIDES WITH MUTANT HUMAN IgG4
|
|
KR20200015511A
(ko)
*
|
2017-05-05 |
2020-02-12 |
알라코스 인크. |
염증성 위장 장애를 치료하기 위한 방법 및 조성물
|
|
CN110831628A
(zh)
|
2017-05-05 |
2020-02-21 |
爱乐科斯公司 |
用于治疗过敏性眼病的方法和组合物
|
|
CN110799543A
(zh)
|
2017-06-26 |
2020-02-14 |
百济神州有限公司 |
肝细胞癌的免疫治疗
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
RU2646807C1
(ru)
*
|
2017-08-08 |
2018-03-07 |
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" |
Способ выделения аутоантител подклассов иммуноглобулина G к иммунорегуляторному цитокину фактору некроза опухоли
|
|
US11572409B2
(en)
|
2017-09-21 |
2023-02-07 |
Imcheck Therapeutics Sas |
Antibodies having specificity for BTN2 and uses thereof
|
|
SG11202003833TA
(en)
|
2017-11-01 |
2020-05-28 |
Chugai Pharmaceutical Co Ltd |
Antibody variant and isoform with lowered biological activity
|
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
US11312781B2
(en)
|
2018-01-24 |
2022-04-26 |
Capella Bioscience Ltd. |
Antigen binding molecules that bind LIGHT
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
FI3844189T3
(fi)
|
2018-08-31 |
2025-03-05 |
Regeneron Pharma |
Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää
|
|
JP6800191B2
(ja)
*
|
2018-09-21 |
2020-12-16 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
JP7612571B2
(ja)
|
2018-10-03 |
2025-01-14 |
ゼンコア インコーポレイテッド |
Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
|
KR20210122810A
(ko)
|
2019-01-31 |
2021-10-12 |
사노피 바이오테크놀로지 |
청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
|
|
BR112021016955A2
(pt)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
|
|
US12258400B2
(en)
|
2019-03-20 |
2025-03-25 |
Imcheck Therapeutics Sas |
Antibodies having specificity for BTN2 and uses thereof
|
|
EP3959240A1
(en)
|
2019-04-24 |
2022-03-02 |
Sanofi Biotechnology |
Methods of diagnosis and treatment of rheumatoid arthritis
|
|
AU2020288561A1
(en)
|
2019-06-04 |
2021-12-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
US12319745B2
(en)
|
2019-07-16 |
2025-06-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for CD38 and uses thereof
|
|
DK4001303T3
(da)
*
|
2019-07-18 |
2025-08-04 |
Hanmi Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af langtidsvirkende lægemiddelkonjugat ved fremstilling af et nyt mellemprodukt
|
|
WO2021058763A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CA3158491A1
(en)
*
|
2019-10-24 |
2021-04-29 |
Novago Therapeutics Ag |
Novel anti-nogo-a antibodies
|
|
WO2021175954A1
(en)
|
2020-03-04 |
2021-09-10 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btnl8 and uses thereof
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
WO2022079199A1
(en)
|
2020-10-15 |
2022-04-21 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
KR20230148956A
(ko)
*
|
2022-04-19 |
2023-10-26 |
전남대학교산학협력단 |
플라젤린 및 면역글로불린 Fc 융합 단백질을 포함하는 간 질환 또는 대사증후군 치료용 조성물
|
|
KR20230148959A
(ko)
*
|
2022-04-19 |
2023-10-26 |
전남대학교산학협력단 |
플라젤린 및 면역글로불린 Fc 융합 단백질을 포함하는 대장염 치료용 조성물
|
|
KR20250018382A
(ko)
|
2022-05-30 |
2025-02-05 |
한올바이오파마주식회사 |
안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
|
|
WO2024115935A1
(en)
|
2022-11-29 |
2024-06-06 |
Inserm |
Methods for the treatment of b-cell lymphoma using cd39 inhibitors
|
|
CN118307670A
(zh)
*
|
2023-01-06 |
2024-07-09 |
广东东阳光药业股份有限公司 |
抗il-11细胞因子人源化抗体
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
WO2024175760A1
(en)
|
2023-02-24 |
2024-08-29 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of endometriosis
|
|
TW202504919A
(zh)
|
2023-05-30 |
2025-02-01 |
美商派拉岡醫療公司 |
α4β7整合素抗體組合物及使用方法
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
WO2025162964A1
(en)
|
2024-01-30 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of endometriosis
|